Mylan has filed two petitions for inter partes review of Sanofi’s patents related to insulin glargine: IPR2017-01526 on U.S. Patent 7,476,652, and IPR2017-01528 on U.S. Patent 7,713,930. Insulin glargine is marketed under the tradename Lantus®.
As we have reported, both the ‘652 and ‘930 patents are the subject of litigation pending in the District of Delaware: Sanofi-Aventis U.S. v. Merck Sharpe and Dohme Corp., No. 16-00812.
These petitions and selected other documents related to IPR of patents related to biologic products are posted on our IPR tracker page.